RE:RE:RE:Warrantsskier59 wrote: Sorry BM75 but I totally disagree with that statement. The earliest we will start to get results is 3 months after treatment and then after 1 year. So first completed patient Phase2 studies will be Summer 2020. I'm sure they have all the locations identified that will participate in the Phase2 in Canada and lining up patients will be quick and easy after the great success we had with the Phase 1b. I'm contacting my friend tonight to try and get his Father into the study.
BlueMetal75 wrote: toade1313 wrote: I do not have any warrants BUT if i did why would I want to sell them now? Why wouldn't i wait til the stock goes to a much, much higher level?
That's why the warrants come with an expiration date, to force the holder to make a decision. My warrants expire in a year, so I will probably take a look at the stock in the first quarter of next year and decide what to do. I'm in this investment for the long haul, and we still have quite a ways to go.
The earliest we will get the first results from this Phase II Trial will be the beginning of 2021. So we have YEARS to go yet...and that's if everything goes right!
As for a Phase I on another indication, I'll believe it when I see it. Recall how many years it took to get the bladder cancer Phase I done - we spent all of 2016 just trying to get the laser device approved!
Settlle in, this will need years yet to play out. Hopefully we get a steady uptrend in the meantime, as we get more press. We shall see.
Skier,
Let's say we are treating our first patients by end of June. Then six months later (at end of 2019) they get the second treatment. And since the point of the study is to evaluate CR after 12 months, you have to then add a year. That takes you to end of 2020 at the earliest, for the first results on the first group of patients. But more realistically (esp with the history of this company) you're looking at 1Q2021.
And again, that's if everything goes right! There's a reason the company states that the Phase II Trial is scheduled to conclude in 4Q2021. It is what it is.